103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC

DCF Advisers LLC purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 103,736 shares of the biopharmaceutical company’s stock, valued at approximately $1,670,000. DCF Advisers LLC owned 0.14% of Xencor at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its holdings in shares of Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. acquired a new stake in Xencor during the 2nd quarter worth approximately $79,000. iSAM Funds UK Ltd purchased a new position in Xencor in the second quarter valued at approximately $122,000. Prelude Capital Management LLC purchased a new position in Xencor in the third quarter valued at approximately $139,000. Finally, Creative Planning lifted its position in Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 3,661 shares in the last quarter.

Get Xencor alerts:

Xencor Price Performance

Xencor stock opened at $27.52 on Thursday. Xencor, Inc. has a 12-month low of $7.13 and a 12-month high of $27.59. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -12.68 and a beta of 0.85. The firm’s fifty day moving average price is $17.61 and its 200 day moving average price is $13.99.

Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.41) EPS. Analysts forecast that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on XNCR. Royal Bank Of Canada raised their target price on shares of Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Truist Financial lowered their target price on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Xencor has an average rating of “Hold” and an average price target of $24.86.

View Our Latest Research Report on Xencor

Xencor Company Profile

(Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

Recommended Stories

• Five stocks we like better than Xencor
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.